UCB SA (OTCMKTS:UCBJY) Short Interest Update

UCB SA (OTCMKTS:UCBJY) saw a large decline in short interest in November. As of November 15th, there was short interest totalling 800 shares, a decline of 73.3% from the October 31st total of 3,000 shares. Based on an average daily volume of 58,500 shares, the short-interest ratio is currently 0.0 days.

UCB Stock Up 2.3 %

Shares of OTCMKTS UCBJY opened at $97.55 on Friday. UCB has a one year low of $36.70 and a one year high of $99.40. The company’s fifty day moving average is $93.71 and its two-hundred day moving average is $84.13. The company has a debt-to-equity ratio of 0.33, a quick ratio of 0.78 and a current ratio of 1.19.

UCB Company Profile

UCB SA, a biopharmaceutical company, develops products and solutions for people with neurology and immunology diseases worldwide. The company's primary products include Cimzia for inflammatory TNF mediated diseases, as well as ankylosing spondylitis, axial spondyloarthritis, Crohn's disease, non-radiographic axial spondyloarthritis, plaque psoriasis, psoriatic arthritis, and rheumatoid arthritis; Vimpat, Keppra, and Briviact for epilepsy; Neupro for Parkinson's disease and restless legs syndrome; Nayzilam, a nasal spray rescue treatment for epilepsy seizure clusters; and Zyrtec and Xyzal for allergies.